BioCentury
ARTICLE | Company News

Cornerstone Therapeutics, EKR deal

July 2, 2012 7:00 AM UTC

Cornerstone acquired EKR for $125 million in cash plus up to $25 million in milestones over the next three years (see BioCentury, May 21). ...